REVB Q2 2023 Earnings — Revelation Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

REVBRevelation Biosciences, Inc.

$2M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$6,262

Operating Income

-$2M

Net Income

-$1M

EPS (Diluted)

$-119.60

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$59,435

Balance Sheet

Total Assets

$16M

Total Liabilities

$5M

Stockholders' Equity

$11M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$6,262	-$6,262	+0.0%
Operating Income	-$2M	-$2M	-3.9%
Net Income	-$1M	-$2M	+21.1%